Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

This biotech stock offers a compelling risk-reward proposition.

My Hands-Down Favorite Stock to Buy in September

The past looks encouraging for the future.

Are We in a New Bull Market or a Bear Market Bounce? Here's What History Shows

Signify Health

Iovance Biotherapeutics

1Life Healthcare

Regeneron Pharmaceuticals

Shares of Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ) closed the week down about 2.5%, losing out on earlier gains during the week. However, retail investors haven't lost hope in ARKK, or Cathie Wood just yet.

5 Top Stocks Cathie Wood Is Selling This Week

Archer-Daniels-Midland Company

Cardinal Health

CF Industries Holdings

Corteva Inc

Enphase Energy

Lamb Weston Hlds

McKesson

Mosaic

Nielsen Hlds

It's been almost all about energy stocks in the S&P 500 this year. But not entirely.

10 Stocks (Not In The Energy Sector) Are Up 30% Or More This Year

Dollar General

Enterprise Products Partners

Inflation won't hurt these stocks and could actually help some of them.

3 Stocks to Buy That Are Practically Inflation-Proof

This top biotech has a lot to like, but will things change in the next 12 months?

Where Will Vertex Pharmaceuticals Be in 1 Year?

Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?

Advanced Micro Devices

Blackstone Group

Cigna

Moderna

ServiceNow

NVIDIA

Tesla

Uber

Sales growth is a very important financial metric that investors consider before making a buy decision.

These Are The Biggest Companies with Over 30% Sales Growth

PayPal

Peak inflation usually serves as a major catalyst for the stock market.

Did a Surefire Signal to Buy Stocks Just Flash?

Just because a stock doesn't work the first time doesn't mean you shouldn't try again. The post VRTX Stock Provides Multiple Swing Trading Lessons appeared first on Investor's Business Daily.

VRTX Stock Provides Multiple Swing Trading Lessons

Major Medicare changes shouldn't impact this big biotech.

Big Pharma Upheaval Coming -- This Stock Is Poised to Skyrocket, Anyway

Vertex Pharmaceuticals is showing is showing green check marks across the board, and today we will look at a bullish option strategy. The post Bull Call Spread On Vertex Pharmaceuticals Taps Into Stock's Newfound Strength appeared first on Investor's Business Daily.

Bull Call Spread On Vertex Pharmaceuticals Taps Into Stock's Newfound Strength

Vertex Pharmaceuticals made a bullish move on earnings amid a confirmed market rally, leading five stocks to watch this week. The post Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch appeared first on Investor's Business Daily.

Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch

Vertex's unique pipeline is going against the modern biotech grain. Valuation and risk metrics are favorable compared to the industry.

Vertex Q2: Betting Big On Quality Over Quantity

The stock market fell sharply early Friday on news of strong job growth in July, but indexes pared losses by the close. The post Stock Market Takes Bullish Jobs Report In Stride; Vertex Pharmaceuticals Finds Support After Earnings appeared first on Investor's Business Daily.

Stock Market Takes Bullish Jobs Report In Stride; Vertex Pharmaceuticals Finds Support After Earnings

The company's popular Trikafta continues to boost the fundamentals.

Why Vertex Pharmaceuticals Stock Was Soaring Today

Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.

Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Charles Wagner - EVP & CFO Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & COO Conference Call Participants Salveen Richter - Goldman Sachs Group Michael Yee - Jefferies Liisa Bayko - Evercore ISI Geoffrey Meacham - Bank of America Merrill Lynch Brian Abrahams - RBC Capital Markets Hartaj Singh - Oppenheimer Olivia Brayer - Cantor Fitzgerald & Co. Mohit Bansal - Wells Fargo Securities David Risinger - SVB Securities Evan Seigerman - BMO Capital Markets Colin Bristow - UBS Operator Good day, and welcome to the Vertex Pharmaceuticals Second Quarter 2022 Earnings Call. [Operator Instructions].

Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2022 Results - Earnings Call Transcript

Vertex (VRTX) delivered earnings and revenue surprises of 3.45% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates

Vertex Pharmaceuticals said its triple-regimen in cystic fibrosis is gaining new users abroad. VRTX stock jumped late Thursday.

Vertex Pharma Easily Beats Quarterly Forecasts And Raises 2022 Outlook

BOSTON--(BUSINESS WIRE)--Vertex Reports Second Quarter 2022 Financial Results

Vertex Reports Second Quarter 2022 Financial Results

Catalent

HEICO

Eli Lilly

Cheniere Energy

Lantheus Holdings

New Fortress Energy

Ollie's Bargain Outlet Hlds

Quanta Services

UnitedHealth Group

With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones. The post Watch These Leaders With Earnings Due, Buy Zones In Focus appeared first on Investor's Business Daily.

Watch These Leaders With Earnings Due, Buy Zones In Focus

My Top Stock to Buy If We're in a Recession

Apple

STAAR Surgical

These companies have cornered the right markets and are chasing the right long-term trends.

3 Winning Evergreen Stocks to Buy and Hold for the Next 25 Years

Assurant

FTI Consulting

Grocery Outlet

Incyte

Coca-Cola

Leidos Hld

Neurocrine Biosciences

T-Mobile US

The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just months away, it's likely the volatility is going to remain for the time being. Investors looking for a smoother market ride should consider buying low-volatility stocks as a way to manage risk.

News for Vertex Pharmaceuticals Stock (VRTX)